Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol-Myers Squibb cites FDA monograph review in defending Excedrin safety.

This article was originally published in The Tan Sheet

Executive Summary

BRISTOL-MYERS CITES OTC MONOGRAPH REVIEW IN SUPPORT OF EXCEDRIN SAFETY in responding to a position paper presented by the National Kidney Foundation at an OTC "feedback" meeting in Rockville, Md. on March 8. In a prepared statement delivered at the meeting, Bristol-Myers Squibb Executive Medical Director-Worldwide Consumer Medicines Howard Hoffman, MD, alluded to FDA's recently completed review of caffeine as an analgesic adjuvant when he said the agency has "corroborated" the company's position that Excedrin and combination analgesics are safe.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS084880

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel